MedTrace Logo

Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years

NCT01596413 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-07-26

No results posted yet for this study

Summary

The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.

Conditions

  • Chemotherapy Induced Nausea and Vomiting

Interventions

DRUG

Sancuso

granisetron transdermal system

DRUG

IV granisetron

IV

Sponsors & Collaborators

  • Kyowa Kirin Pharmaceutical Development Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01596413 on ClinicalTrials.gov